ITGAX and neoplasm: To this end, KRASG12D tumours treated with atorvastatin were immunostained for P-AKT and MAC2, the latter of which was used as a marker for both CD11c+ IMC/TAMs (Kamata et al., 2015, 2020) and Ly6C+ monocytes/M-MDSCs (Movahedi et al., 2008; Yu et al., 2016).